LINC00837: A Drug Target / Disease Biomarker (G100507605)

Target Name: LINC00837

NCBI ID: G100507605

LINC00837

Other Name(s): long intergenic non-protein coding RNA 837 | Long intergenic non-protein coding RNA 837, transcript variant 1 | RP11-478H13.2

LINC00837: A Drug Target / Disease Biomarker

LINC00837 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the key features of LINC00837 is its ability to interact with other proteins, particularly with the transcription factor NF-kappa-B. NF-kappa-B is a protein that plays a role in regulating gene expression, and is known to play a key role in the development and progression of a number of diseases, including cancer.

Research has shown that LINC00837 and NF-kappa-B can interact in a number of ways. For example, studies have shown that LINC00837 can physically interact with NF-kappa-B, and that this interaction can modulate the activity of NF-kappa-B. Additionally, research has shown that LINC00837 can alter the expression of genes that are regulated by NF-kappa-B, including those that are involved in cell growth and differentiation.

The precise mechanisms by which LINC00837 and NF-kappa-B interact are not well understood, and more research is needed to fully determine the role of LINC00837 in these processes. However, the potential implications of LINC00837's interaction with NF-kappa-B are significant, and suggest that it may be a useful target for the development of new therapies for a number of diseases.

In addition to its potential as a drug target, LINC00837 is also a potential biomarker for a number of diseases. For example, studies have shown that LINC00837 is downregulated in a number of cancer tissues, and that this downregulation is associated with poor prognosis. Additionally, research has shown that LINC00837 is also downregulated in neurodegenerative diseases, and that this downregulation is associated with the severity of these conditions.

Overall, the potential of LINC00837 as a drug target and biomarker is significant, and suggests that it may be a valuable tool for the development of new therapies for a number of diseases. Further research is needed to fully understand the mechanisms by which LINC00837 interacts with NF-kappa-B, and to determine its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 837

The "LINC00837 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00837 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets